Newsfeeds - Spark Newswire

1 minute read

Immunocore Announces Initial Phase 1 Data Of ImmTAC Candidate IMC-C103C Targeting MAGE-A4

Today, 5:07 PM

Immunocore announces initial Phase 1 data of ImmTAC® candidate IMC-C103C targeting MAGE-A4 Clinical activity with confirmed durable responses in ovarian cancer and a confirmed durable response in HNSCC Manageable

IMCR

6 minute read

The Daily Biotech Pulse: Valneva Inks COVID-19 Vaccine Supply Contract In Europe, I-Mab Spikes On China Deal, DermTech Sinks On Guidance

By Shanthi Rexaline

Today, 5:07 PM

Here's a roundup of top developments in the biotech space over the last 24 hours.

ACIU

1 minute read

Immunocore Holdings Q3 EPS $(0.93), Sales $8.00M

By Benzinga Newsdesk

Today, 5:07 PM

Immunocore Holdings (NASDAQ:IMCR) reported quarterly losses of $(0.93) per share. The company reported $8.00 million in sales this quarter.

IMCR

2 minute read

Events
News

Immunocore Presents New Data On Tebentafusp In Metastatic Cutaneous Melanoma And Uveal Melanoma At The Society For Immunotherapy Of Cancer 36th Annual Meeting

By Benzinga Newsdesk

Today, 5:07 PM

Immunocore Holdings Plc (NASDAQ:IMCR), a late-stage biotechnology company pioneering the development of a novel class of T cell receptor (TCR) bispecific immunotherapies designed to treat a broad range of diseases,

IMCR

12 minute read

Benzinga’s Top Ratings Upgrades, Downgrades For October 20, 2021

By Benzinga Insights

Today, 5:07 PM

Upgrades

AGL

1 minute read

Oppenheimer Initiates Coverage On Immunocore Holdings with Outperform Rating, Announces Price Target of $56

By Benzinga Newsdesk

Today, 5:07 PM

Oppenheimer analyst Justin Kim initiates coverage on Immunocore Holdings (NASDAQ:IMCR) with a Outperform rating and announces Price Target of $56.

IMCR

4 minute read

The Daily Biotech Pulse: Restricted Authorization For Pfizer’s COVID-19 Booster Dose, AbCellera Strikes Antibody Licensing Deal, Solid Biosciences Issues DMD Data

By Shanthi Rexaline

Today, 5:07 PM

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 22)

ABCL

1 minute read

Immunocore Tebentafusp Shows Survival Benefit In Untreated Eye Cancer Patients

By Vandana Singh

Today, 5:07 PM

Immunocore Holdings Plc (NASDAQ:IMCR) announced that data from a Phase 3 randomized trial comparing tebentafusp (IMCgp100) with investigator’s choice…

IMCR

2 minute read

News

Immunocore Presents Data At The European Society For Medical Oncology Congress 2021 Demonstrating A Reduction In Circulating Tumor DNA While On Tebentafusp Is Associated With Overall Survival In The Phase 2 Clinical Trial

By Benzinga Newsdesk

Today, 5:07 PM

IMCR

1 minute read

News

Immunocore Announces UK’s Medicines and Healthcare Products Regulatory Agency Accepts Marketing Authorization Application for Tebentafusp in Metastatic Uveal Melanoma

By Benzinga Newsdesk

Today, 5:07 PM

Immunocore Announces UK's Medicines and Healthcare Products Regulatory Agency (MHRA) Accepts Marketing Authorization Application for Tebentafusp in Metastatic Uveal

IMCR